Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | FPR1 | P21462 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213697 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4EMIFRNPEPHPGD | |
| SCHEMBL14443169 | 0.83 | ALDH1A1 (0.47) | ALDH1A1KDM4EMIFHPGDSMN1; SMN2 | |
| SCHEMBL4164865 | 0.81 | ALDH1A1 (0.40) | ALDH1A1HPGDJAK2EGFRL3MBTL1 | |
| SCHEMBL4164862 | 0.81 | ALDH1A1 (0.40) | ALDH1A1HPGDJAK2EGFRL3MBTL1 | |
| SCHEMBL5246164 | 0.81 | ALDH1A1 (0.43) | ALDH1A1JAK2EGFRL3MBTL1GAA | |
| SCHEMBL5246160 | 0.81 | ALDH1A1 (0.43) | ALDH1A1JAK2EGFRL3MBTL1GAA | |
| SCHEMBL5219201 | 0.79 | CTSA (0.39) | — | |
| SCHEMBL5219207 | 0.79 | CTSA (0.39) | — | |
| SCHEMBL4174586 | 0.77 | FDPS (0.44) | ALDH1A1JAK2EGFRSMN1; SMN2 | |
| SCHEMBL4174581 | 0.77 | FDPS (0.44) | ALDH1A1JAK2EGFRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259163-B2 | 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors | GLAXO GROUP LIMITED (GB) | 2007-08-21 | — | — | US | disclosed |
| EP-1440069-B1 | 4-(6-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20050043390-A1 | 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043390-A1 | 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors | NR1H3, NR1H2, NR1I3 | ALDH1A1 215/4885KDM4E 2817/4885MIF 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.